Advertisements



Sorrento Therapeutics expands clinical development of resiniferatoxin

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 15th, 2019

Sorrento Therapeutics says Phase 1b resiniferatoxin trial met day 84 goals

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 19th, 2019

Sorrento Therapeutics to accelerate human IND filing of resiniferatoxin

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 10th, 2019

miRagen Therapeutics to Report First Quarter 2019 Financial Results and Host a Conference Call on May 8th

BOULDER, Colo., April 25, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of R.....»»

Category: earningsSource: benzingaApr 25th, 2019

Sangamo Therapeutics, Inc. (SGMO) Sangamo Clinical Development Update Conference Call (Transcript)

Sangamo Therapeutics, Inc. (SGMO) Sangamo Clinical Development Update Conference Call (Transcript).....»»

Category: topSource: seekingalphaApr 6th, 2019

The Wall Street Journal: Sorrento Therapeutics sues billionaire Soon-Shiong over development of cancer drug

Sorrento Therapeutics Inc. alleges billionaire Patrick Soon-Shiong and .....»»

Category: topSource: marketwatchApr 3rd, 2019

Y-mAbs Announces 2018 Financial Results and Corporate Development Highlights

NEW YORK, March 22, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a late-stage clinical bioph.....»»

Category: earningsSource: benzingaMar 22nd, 2019

Trillium Therapeutics Reports First Quarter 2018 Financial and Operating Results

Focusing TTI-621 clinical development on T.....»»

Category: earningsSource: benzingaMay 11th, 2018

Anchiano Therapeutics Reports Third Quarter 2018 Financial and Operational Results

CAMBRIDGE, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced op.....»»

Category: earningsSource: benzingaNov 19th, 2018

Protagonist Therapeutics to begin clinical development of PN-10943

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 27th, 2018

ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019

Geneva, Switzerland and Boston, MA –February 27, 2019 - ObsEva SA (NASDAQ:OBSV), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman.....»»

Category: earningsSource: benzingaFeb 27th, 2019

Sarepta doubles down on gene therapies after early Limb-Girdle data

As some biotechs struggle to meet the expectations placed upon gene therapies, Sarepta Therapeutics is investing further in the field, announcing a deal to purchase its development partner for $165 million after positive early clinical trial data. .....»»

Category: topSource: bizjournalsFeb 27th, 2019

Analysts Laud Sarepta"s "Increasingly Active" Gene Therapy Clinical Development

Sarepta Therapeutics Inc (NASDAQ: SRPT) reported fourth-quarter results Wednesday alongside positive results for its muscular dystrophy gene therapy candidate. .....»»

Category: blogSource: benzingaFeb 28th, 2019

Avalon"s AVA-101 to enter pre-clinical process development phase in Q3

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 15th, 2019

Fulcrum Therapeutics IPO: What You Need To Know

The week's IPO slate consists of a handful of biotechs, and among them is a clinical-stage biotech company focused on genetic disorders. read more.....»»

Category: blogSource: benzingaJul 14th, 2019

Tetra Tech (TTEK) Acquires UK-Based WYG, Expands Presence

Tetra Tech's (TTEK) takeover of WYG will allow it to boost its international development business for the U.K.'s Department for International Development.....»»

Category: worldSource: nytJul 10th, 2019

CorMedix says Neutrolin Phase 3 clinical development complete after FDA feedback

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 9th, 2019

TOTAL (TOT) Expands Operation in Kazakhstan"s Dunga Project

TOTAL (TOT) and its partners approve the Phase 3 development of Dunga field in western Kazakhstan, which in a way will contribute to TOTAL's goal to increas.....»»

Category: personnelSource: nytJul 4th, 2019

FDA Places Unum"s Early Stage Cancer Drug Trial On Clinical Hold

Unum Therapeutics Inc (NASDAQ: UMRX) shares were under pressure Wednesday following a clinical trial update provided by the company late Tuesday. read more.....»»

Category: blogSource: benzingaJul 3rd, 2019

Unum Therapeutics shares overreacted to clinical hold, says H.C. Wainwright

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 3rd, 2019

Unum Therapeutics clinical hold not an issue, says Cowen

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 3rd, 2019